Cerus Corp (CERS) Says FDA Accepted IDE Supplement for INTERCEPT Blood System Treatment of Ebola
Tweet Send to a Friend
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has accepted Cerus’ clinical protocol to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
